Thursday, January 30, 2014
Reports for around 300 global stocks flowed through Skaffold during January, including Apple, Microsoft, Procter and Gamble, AT&T, Facebook, Intel, The Boeing Company, eBay, Nike, Caterpillar, Starbucks, Kimberly Clark, Yahoo!, Motorola, Xerox, Oshkosh, The Bank of Nova Scotia, Metro Inc, Prada, Singapore Exchange, PZ Cussons and SGS Societe Generale de Surveillance.
Exclusively for Skaffold members, we’ve put together a list of companies whose latest financial results are now available in Skaffold, including updated Skaffold Scores and Safety Margins.
Thursday, May 02, 2013
ResMed has been a hot topic at Skaffold lately, partly because the company recently released its third quarter results to the NYSE. Some market commenters have gone so far as to liken ResMed to Australian greats Cochlear (COH) and CSL. ResMed’s business fundamentals have shown strong performance recently, and Skaffold suggests future growth in intrinsic value of more than 16% per annum.
Whilst the market price of US$48 is well above today’s intrinsic value estimate of close to US$30, and even the 2015 estimate of circa $41.50, given RMD’s strong track record and future growth prospects, it may be a stock worth keeping an eye on in case a price correction should occur in the future.